Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epigenomics AGFRA:ECX -8.08%20 EV-to-OCF is -22.10 as of Aug. 16, 2026. GuruFocus rates FRA:ECX with a GF Score™ of 20/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Epigenomics AG ranks better than 88.68% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Epigenomics AG's Enterprise Value is €11.78 Mil.
Epigenomics AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.53 Mil. Therefore, Epigenomics AG's EV-to-OCF for today is -22.10.
The historical rank and industry rank for Epigenomics AG's EV-to-OCF or its related term are showing as below:
FRA:ECX'
s EV-to-OCF Range Over the Past 10 Years
Min: -22.88 Med: -1.94 Max: 4.67
Current: -22.1
During the past 13 years, the highest EV-to-OCF of Epigenomics AG was 4.67. The lowest was -22.88. And the median was -1.94.
FRA:ECX's EV-to-OCF is ranked better than 88.68% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.235
vs FRA:ECX: -22.10
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Epigenomics AG's PE Ratio (TTM) for today is calculated as:
Epigenomics AG's share price for today is €0.91.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epigenomics AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.351.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Epigenomics AG EV-to-OCF Related Terms
Epigenomics AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Epigenomics AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's EV-to-OCF falls into.
Epigenomics AG's current Enterprise Value is €11.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epigenomics AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG (FRA:ECX) has a EV-to-OCF of -22.10 as of Aug. 16, 2026. According to the industry distribution chart, Epigenomics AG ranks #24 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 11.3%.
Is Epigenomics AG's EV-to-OCF too high?
Epigenomics AG's current EV-to-OCF is -22.10. Based on the distribution chart, Epigenomics AG ranks #24 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Epigenomics AG has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #24 out of 212 companies for EV-to-OCF. This places Epigenomics AG in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 6.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.24, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current EV-to-OCF is -22.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.91 — trading 911.1% above its estimated fair value. The current EV-to-OCF is -22.10. Epigenomics AG's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current EV-to-OCF is -22.10 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.91 is trading 911.1% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
EV-to-OCF: -22.10
GF Value™: €0.09 vs. price of €0.91 (911.1% above fair value)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
20GF Score
Get the complete analysis for FRA:ECX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
